Literature DB >> 33103195

Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19).

Jakob Malsy1, Luzia Veletzky1, Janna Heide1,2, Annette Hennigs1, Ines Gil-Ibanez1, Alexander Stein3,4, Marc Lütgehetmann2,5, Ulrich Rosien6, Dorothea Jasper6, Sven Peine7, Jens Hiller7, Friedrich Haag8, Stefan Schmiedel1, Samuel Huber1, Sabine Jordan1, Marylyn M Addo1,2, Julian Schulze Zur Wiesch1,2.   

Abstract

We provide detailed clinical, virological, and immunological data of a B-cell-depleted patient treated with obinutuzumab for follicular lymphoma with protracted coronavirus disease 2019 (COVID-19) and viremia. A sustained response was achieved after 2 courses of remdesivir and subsequent convalescent plasma therapy. Immunocompromised patients might require combined and prolonged antiviral treatment regimens.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; convalescent plasma; follicular lymphoma; obinutuzumab; remdesivir

Mesh：

Substances：

Year:  2021        PMID： 33103195      PMCID： PMC7665388          DOI： 10.1093/cid/ciaa1637

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  18 in total

1.  Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse.

Authors:  Rohan M Prasad; Shaurya Srivastava; Enhua Wang; Jason Z Liu; Rakesh Gami; Ayat Abdelgadir; Akhil Sharma; Sumugdha Rayamajhi; Richa Tikaria
Journal:  Perm J       Date:  2021-10-29

2.  Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.

Authors:  Ferenc Magyari; László Imre Pinczés; Béla Nagy; Árpád Illés; Edit Páyer; Katalin Farkas; Szilvia Ujfalusi; Ágnes Diószegi; Máté Sik; Zsófia Simon; Gergely Nagy; Zsuzsanna Hevessy
Journal:  Ann Hematol       Date:  2022-07-14       Impact factor: 4.030

Review 3.  Use of convalescent plasma in COVID-19 patients with immunosuppression.

Authors:  Jonathon W Senefeld; Stephen A Klassen; Shane K Ford; Katherine A Senese; Chad C Wiggins; Bruce C Bostrom; Michael A Thompson; Sarah E Baker; Wayne T Nicholson; Patrick W Johnson; Rickey E Carter; Jeffrey P Henderson; William R Hartman; Liise-Anne Pirofski; R Scott Wright; De Lisa Fairweather; Katelyn A Bruno; Nigel S Paneth; Arturo Casadevall; Michael J Joyner
Journal:  Transfusion       Date:  2021-06-01       Impact factor: 3.337

Review 4.  Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature.

Authors:  Marcial Delgado-Fernández; Gracia Mar García-Gemar; Ana Fuentes-López; Manuel Isidro Muñoz-Pérez; Salvador Oyonarte-Gómez; Ignacio Ruíz-García; Jessica Martín-Carmona; Jaime Sanz-Cánovas; Manuel Ángel Castaño-Carracedo; José María Reguera-Iglesias; Juan Diego Ruíz-Mesa
Journal:  Enferm Infecc Microbiol Clin (Engl Ed)       Date:  2021-02-11

5.  Predictors of intensive care unit admission in patients with Legionella pneumonia: role of the time to appropriate antibiotic therapy.

Authors:  Marco Falcone; Alessandro Russo; Giusy Tiseo; Mario Cesaretti; Fabio Guarracino; Francesco Menichetti
Journal:  Infection       Date:  2020-12-14       Impact factor: 3.553

Review 6.  The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis.

Authors:  Stephen A Klassen; Jonathon W Senefeld; Patrick W Johnson; Rickey E Carter; Chad C Wiggins; Shmuel Shoham; Brenda J Grossman; Jeffrey P Henderson; James Musser; Eric Salazar; William R Hartman; Nicole M Bouvier; Sean T H Liu; Liise-Anne Pirofski; Sarah E Baker; Noud van Helmond; R Scott Wright; DeLisa Fairweather; Katelyn A Bruno; Zhen Wang; Nigel S Paneth; Arturo Casadevall; Michael J Joyner
Journal:  Mayo Clin Proc       Date:  2021-02-17       Impact factor: 7.616

7.  Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.

Authors:  Yusri Taha; Hayley Wardle; Matthias L Schmid; Christopher J A Duncan; Adam B Evans; Ewan R Hunter; Helen Marr; Wendy Osborne; Matthew Bashton; Darren Smith; Shirelle Burton-Fanning
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-12-30       Impact factor: 6.781

8.  COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review.

Authors:  Jessica M Jones; Aiman J Faruqi; James K Sullivan; Cassandra Calabrese; Leonard H Calabrese
Journal:  Pathog Immun       Date:  2021-05-14

9.  SARS-CoV-2 Persistent Viral Shedding in the Context of Hydroxychloroquine-Azithromycin Treatment.

Authors:  Michel Drancourt; Sébastien Cortaredona; Cléa Melenotte; Sophie Amrane; Carole Eldin; Bernard La Scola; Philippe Parola; Matthieu Million; Jean-Christophe Lagier; Didier Raoult; Philippe Colson
Journal:  Viruses       Date:  2021-05-12       Impact factor: 5.818

Review 10.  Impact of COVID-19 in patients with lymphoid malignancies.

Authors:  John Charles Riches
Journal:  World J Virol       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.